who give a #$%$ of analysts upgrade or downgrade, the most importing thing right now is the FDA approval and when the first revenue rolling in.. the rest is history .. analysts are not accountable for being wrong, why do you put too much faith in these MFers..?. GL
DNDN, CLDN, IMMU and many other immu players with BTD took investors to the cleaner.. paid pumpers constant pumping on MB and other blogger outlets like MF, SA.. showing misleading articles, or analysts bogus upgraded to justify outrages marketcaps.
Bio companies use cancer therapy as the theme to scam investors, NONE of the cancer treatment works, just marginally prolongs a few months of life.. Hedge funds, and Bio founders get rich while investors holding the bag.. GL
were you born a natural a**hole? remember to look in the mirror and call yourself an a**hole eveyday heh!! LMAO
That is the only way CNN can classify the massacre was due to mental illness.. if a massacre was committed by a Muslim, then it is classified as an act of a terrorist.. if a massacre was committed by minorities, then it is classified as an act of a street thug..
Of course, we have no solution for 95% of the massacres committed by mental illness, but we have many solutions for terrorism and street thugs, don't we.. go figure ..
ccsrqpcr, you're ffff moron.. you can't go back on CLDX MB to read what this paid pumper were posting when the CLDX stock was trading over $30/sh? (Feb- Mar2014) he posted almost daily and even claimed that CLDX has cornered the market for EGFrVII in GBM market.. and his projection was $37-40.. you're just too dump to notice...
long_vrts2 • Mar 2, 2015 1:01 AM Flag
15users liked this postsusers disliked this posts1Reply
The short answer: for EGFRvIII GBM it's winner-take-all, and the winner will be Rintega.
If it appears that CLDX has cornered the market for EGFrVIII in GBM- as well as potentially other cancers that express vIII- it is not by accident. CLDX has strategically chosen cancer markers where they have the field to themselves: GPNMB(TN breast cancer, melanoma, lung cancer...), CD27( potentially at least a dozen cancers), FLT3L, (CDX-1401 is an exception, as there are other players in this segment). I'm not sure to what extent the investor community appreciates this aspect of CLDX's pipeline, but eventually it will become evident as the drug candidates progress through the regulatory pathway to marketing.
long_vrts2 • Mar 3, 2015 12:53 AM Flag
4users liked this postsusers disliked this posts0Reply
I would say in the range of $37-40.
long_vrts2, you're full of scraps.. you have been pounding the table "buy, buy, buy" since CLDX was $30.. no one should listen to your pumping BS.. shut the #$%$ up fool..
another bio-scam.. nothing more.. every time the "good news" is released, they either want another secondary to dilute the shares or stock drops drastically.. in this case, after the announcement, this stock drops 60% in 10 days.
everyday is the last shake out. unfortunately, it keeps shake, shake, shake and it keeps shaking.. stop making a fool of yourself..
hey dilyz, any more reason why you bought in at $13.30? looks like your investment acct sinking to the bottom.. don't tell me another analyst just upgraded to a buy and raised the PT again... LMAO
"go it alone" with 20 employees? over 50% are in management positions. stop making a fool of yourself with these mindless speculations.
can you write another thesis explaining why did you buy in at $13.30 again? you could have bought in at much lower prices, like $11, $10, $9, $8, $7..etc.. M...O,,,R...O....N..
ig, you're so stupid to lose money everyday and still believing that ADXS is still a good investment. How stupid are you?